ArticleCureus2025
An Insight into Clinicopathological Parameters and Prognostic Significance of Double Expressor Diffuse Large B-Cell Lymphoma in a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). A distinct, high-risk subset-double expressor DLBCL shows immunohistochemical (IHC) co-expression of BCL2 and c-MYC. Objective To evaluate the clinicopathological spectrum and prognostic significance of double expressor DLBCL. Methods This retrospective study included 49 patients diagnosed with DLBCL over a four-year period at a tertiary care center. IHC analysis using a non-Hodgkin lymphoma panel was performed, and subtyping was done using the Hans algorithm to classify cases as germinal center B-cell-like (GCB) or non-germinal center B. Double expressor status was defined by IHC expression thresholds for BCL2 and c-MYC. Results Of the 49 cases, 27 (55.1%) were GCB and 22 (44.8%) were non-GCB. Twenty-three patients (46.9%) met criteria for double expressor DLBCL-11 GCB (47.8%) and 12 non-GCB (52.2%). Follow-up data from 27 patients revealed a significantly higher early mortality rate among double expressor cases, particularly within the first six months, suggesting an unfavorable prognosis. Histopathology showed diffuse effacement of lymph node architecture with proliferation of medium- to large-sized atypical lymphoid cells. Conclusion Double expressor DLBCL represents a clinically aggressive variant with a distinctly worse prognosis than DLBCL-not otherwise specified (NOS). Double expressor DLBCL poses a significant prognostic challenge within DLBCL-NOS and must be recognized as a key determinant in patient stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.